留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

心脏移植的过去、现在和未来

郑子赫, 许政, 林炘凡, 等. 心脏移植的过去、现在和未来[J]. 器官移植, 2023, 14(2): 227-234. doi: 10.3969/j.issn.1674-7445.2023.02.008
引用本文: 郑子赫, 许政, 林炘凡, 等. 心脏移植的过去、现在和未来[J]. 器官移植, 2023, 14(2): 227-234. doi: 10.3969/j.issn.1674-7445.2023.02.008
Zheng Zihe, Xu Zheng, Lin Xinfan, et al. The past, present and future of heart transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 227-234. doi: 10.3969/j.issn.1674-7445.2023.02.008
Citation: Zheng Zihe, Xu Zheng, Lin Xinfan, et al. The past, present and future of heart transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 227-234. doi: 10.3969/j.issn.1674-7445.2023.02.008

心脏移植的过去、现在和未来

doi: 10.3969/j.issn.1674-7445.2023.02.008
基金项目: 

国家自然科学基金 82070476

福建省科技创新联合资金项目 2019Y9057

详细信息
    作者简介:
    通讯作者:

    戴小福,Email: daixiaofu719@hotmail.com

  • 中图分类号: R617, R541

The past, present and future of heart transplantation

More Information
  • 摘要: 心脏移植是治疗终末期心力衰竭最有效的策略之一。心脏同种移植面临供心保存困难、排斥反应和术后并发症多等诸多问题。经过数十年的研究和实践,大多问题已得到解决,然而器官短缺问题日益凸显。为缓解器官短缺,人工心脏和心脏异种移植方案受到重视,且近年来获得重大进展。人工心脏应用于临床后极大改善了终末期心力衰竭患者的生存率,有望成为终末期心力衰竭的标准疗法。心脏异种移植还面临许多挑战,距离真正应用于临床还很遥远。本文对心脏移植的历史、心脏同种移植的发展、人工心脏的使用和心脏异种移植的进展做一综述,并对心脏移植未来的发展方向进行展望。

     

  • 图  1  左心室辅助装置植入术

    注:A图为左心室打孔;B图为缝合底座;C图为安装血泵;D图为吻合人工血管和升主动脉。

    Figure  1.  Implantation of left ventricular assist device

  • [1] MA LY, CHEN WW, GAO RL, et al. China cardiovascular diseases report 2018: an updated summary[J]. J Geriatr Cardiol, 2020, 17(1): 1-8. DOI: 10.11909/j.issn.1671-5411.2020.01.001.
    [2] Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2021: an updated summary[J]. Biomed Environ Sci, 2022, 35(7): 573-603. DOI: 10.3967/bes2022.079.
    [3] VAN DER MEER P, GAGGIN HK, DEC GW. ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison[J]. J Am Coll Cardiol, 2019, 73(21): 2756-2768. DOI: 10.1016/j.jacc.2019.03.478.
    [4] SUN YF, WANG ZW, ZHANG J, et al. Current status of and opinions on heart transplantation in China[J]. Curr Med Sci, 2021, 41(5): 841-846. DOI: 10.1007/s11596-021-2444-9.
    [5] REICH H, RAMZY D, MORIGUCHI J, et al. Acceptable post-heart transplant outcomes support temporary MCS prioritization in the new OPTN|UNOS heart allocation policy[J]. Transplant Proc, 2021, 53(1): 353-357. DOI: 10.1016/j.transproceed.2020.04.1819.
    [6] GANAPATHI AM, LAMPERT BC, MOKADAM NA, et al. Allocation changes in heart transplantation: what has really changed? [J]. J Thorac Cardiovasc Surg, 2023, 165(2): 724-733. DOI: 10.1016/j.jtcvs.2021.03.031.
    [7] KIM ST, HELMERS MR, IYENGAR A, et al. Assessing predicted heart mass size matching in obese heart transplant recipients[J]. J Heart Lung Transplant, 2021, 40(8): 805-813. DOI: 10.1016/j.healun.2021.04.020.
    [8] REUL RM JR, ZHANG TS, RANA AA, et al. Consistent improvements in short- and long-term survival following heart transplantation over the past three decades[J]. Clin Transplant, 2021, 35(4): e14241. DOI: 10.1111/ctr.14241.
    [9] KHUSH KK, POTENA L, CHERIKH WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report-2020; focus on deceased donor characteristics[J]. J Heart Lung Transplant, 2020, 39(10): 1003-1015. DOI: 10.1016/j.healun.2020.07.010.
    [10] CHAUHAN D, ORLANDI V, RAJAB TK, et al. Postoperative outcomes in infants undergoing ABO-incompatible heart transplantation in the United States[J]. Ann Thorac Surg, 2022, 114(5): 1746-1752. DOI: 10.1016/j.athoracsur.2021.08.039.
    [11] BEEMAN A, MUTHIALU N. ABO-incompatible heart transplantation in children-a systematic review of current practice[J]. Indian J Thorac Cardiovasc Surg, 2020, 36(Suppl 2): 190-193. DOI: 10.1007/s12055-020-00971-8.
    [12] HUCKABY LV, SEESE LM, HANDZEL R, et al. Center-level utilization of hepatitis C virus-positive donors for orthotopic heart transplantation[J]. Transplantation, 2021, 105(12): 2639-2645. DOI: 10.1097/TP.0000000000003674.
    [13] AWAD MA, SHAH A, GRIFFITH BP. Current status and outcomes in heart transplantation: a narrative review[J]. Rev Cardiovasc Med, 2022, 23(1): 11. DOI: 10.31083/j.rcm2301011.
    [14] HORNUSS D, RUDI A, KOERNER L, et al. HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive liver-grafts to HBV-na?ve recipients: a retrospective study[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101496. DOI: 10.1016/j.clinre.2020.07.003.
    [15] LECHIANCOLE A, VENDRAMIN I, SPONGA S, et al. Influence of donor-transmitted coronary artery disease on long-term outcomes after heart transplantation - a retrospective study[J]. Transpl Int, 2021, 34(2): 281-289. DOI: 10.1111/tri.13793.
    [16] FIORE A, GRANDE AM, GATTI G, et al. Valvular surgery in donor hearts before orthotopic heart transplantation[J]. Arch Cardiovasc Dis, 2020, 113(11): 674-678. DOI: 10.1016/j.acvd.2020.05.010.
    [17] WEVER PINZON O, STODDARD G, DRAKOS SG, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant[J]. Am J Transplant, 2011, 11(12): 2755-2761. DOI: 10.1111/j.1600-6143.2011.03744.x.
    [18] JAWITZ OK, FUDIM M, RAMAN V, et al. Reassessing recipient mortality under the new heart allocation system: an updated UNOS registry analysis[J]. JACC Heart Fail, 2020, 8(7): 548-556. DOI: 10.1016/j.jchf.2020.03.010.
    [19] MULLAN CW, CHOUAIRI F, SEN S, et al. Changes in use of left ventricular assist devices as bridge to transplantation with new heart allocation policy[J]. JACC Heart Fail, 2021, 9(6): 420-429. DOI: 10.1016/j.jchf.2021.01.010.
    [20] WANG Y, CAI J, SUN Y, et al. Extended donor criteria in heart transplantation: a retrospective study from a single Chinese institution[J]. J Thorac Dis, 2018, 10(4): 2153-2165. DOI: 10.21037/jtd.2018.03.149.
    [21] MINASIAN SM, GALAGUDZA MM, DMITRIEV YV, et al. Preservation of the donor heart: from basic science to clinical studies[J]. Interact Cardiovasc Thorac Surg, 2015, 20(4): 510-519. DOI: 10.1093/icvts/ivu432.
    [22] CANNATA A, BOTTA L, COLOMBO T, et al. Does the cardioplegic solution have an effect on early outcomes following heart transplantation? [J]. Eur J Cardiothorac Surg, 2012, 41(4): e48-e53. DOI: 10.1093/ejcts/ezr321.
    [23] GEORGE TJ, ARNAOUTAKIS GJ, BAUMGARTNER WA, et al. Organ storage with University of Wisconsin solution is associated with improved outcomes after orthotopic heart transplantation [J]. J Heart Lung Transplant, 2011, 30(9): 1033-1043. DOI: 10.1016/j.healun.2011.05.005.
    [24] KHUSH KK, PATEL J, PINNEY S, et al. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study [J]. Am J Transplant, 2019, 19(10): 2889-2899. DOI: 10.1111/ajt.15339.
    [25] DENG MC, EISEN HJ, MEHRA MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling [J]. Am J Transplant, 2006, 6(1): 150-160. DOI: 10.1111/j.1600-6143.2005.01175.x.
    [26] VAN AELST LN, SUMMER G, LI S, et al. RNA profiling in human and murine transplanted hearts: identification and validation of therapeutic targets for acute cardiac and renal allograft rejection [J]. Am J Transplant, 2016, 16(1): 99-110. DOI: 10.1111/ajt.13421.
    [27] AMIN AA, ARAJ FG, ARIYAMUTHU VK, et al. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era [J]. Clin Transplant, 2019, 33(8): e13651. DOI: 10.1111/ctr.13651.
    [28] MATAR AJ, CREPEAU RL, MUNDINGER GS, et al. Large animal models of vascularized composite allotransplantation: a review of immune strategies to improve allograft outcomes [J]. Front Immunol, 2021, 12: 664577. DOI: 10.3389/fimmu.2021.664577.
    [29] TONSHO M, LEE S, AOYAMA A, et al. Tolerance of lung allografts achieved in nonhuman primates via mixed hematopoietic chimerism [J]. Am J Transplant, 2015, 15(8): 2231-2239. DOI: 10.1111/ajt.13274.
    [30] VINCENTI F, ROSTAING L, GRINYO J, et al. Belatacept and long-term outcomes in kidney transplantation [J]. N Engl J Med, 2016, 374(4): 333-343. DOI: 10.1056/NEJMoa1506027.
    [31] LIN CH, ANGGELIA MR, CHENG HY, et al. The intragraft vascularized bone marrow component plays a critical role in tolerance induction after reconstructive transplantation [J]. Cell Mol Immunol, 2021, 18(2): 363-373. DOI: 10.1038/s41423-019-0325-y.
    [32] OH BC, FURTMüLLER GJ, FRYER ML, et al. Vascularized composite allotransplantation combined with costimulation blockade induces mixed chimerism and reveals intrinsic tolerogenic potential [J]. JCI Insight, 2020, 5(7): e128560. DOI: 10.1172/jci.insight.128560.
    [33] DURAN-STRUUCK R, SONDERMEIJER HP, BüHLER L, et al. Effect of ex vivo-expanded recipient regulatory T cells on hematopoietic chimerism and kidney allograft tolerance across MHC barriers in cynomolgus macaques [J]. Transplantation, 2017, 101(2): 274-283. DOI: 10.1097/TP.0000000000001559.
    [34] EZZELARAB MB, ZAHORCHAK AF, LU L, et al. Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates[J]. Am J Transplant, 2013, 13(8): 1989-2005. DOI: 10.1111/ajt.12310.
    [35] SCHNIDER JT, WEINSTOCK M, PLOCK JA, et al. Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential[J]. Clin Dev Immunol, 2013: 495212. DOI: 10.1155/2013/495212.
    [36] DETELICH D, MARKMANN JF. The dawn of liver perfusion machines[J]. Curr Opin Organ Transplant, 2018, 23(2): 151-161. DOI: 10.1097/MOT.0000000000000500.
    [37] KHUSH KK, CHERIKH WS, CHAMBERS DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1056-1066. DOI: 10.1016/j.healun.2019.08.004.
    [38] ASLEH R, BRIASOULIS A, SMITH B, et al. Association of aspirin treatment with cardiac allograft vasculopathy progression and adverse outcomes after heart transplantation[J]. J Card Fail, 2021, 27(5): 542-551. DOI: 10.1016/j.cardfail.2021.01.019.
    [39] SPARTALIS M, SPARTALIS E, TZATZAKI E, et al. Cardiac allograft vasculopathy after heart transplantation: current prevention and treatment strategies[J]. Eur Rev Med Pharmacol Sci, 2019, 23(1): 303-311. DOI: 10.26355/eurrev_201901_16777.
    [40] MUDIGONDA P, BERARDI C, CHETRAM V, et al. Implications of cancer prior to and after heart transplantation[J]. Heart, 2022, 108(6): 414-421. DOI: 10.1136/heartjnl-2020-318139.
    [41] CARROZZINI M, BOTTIO T, CARAFFA R, et al. Impact of continuous flow left ventricular assist device on heart transplant candidates: a multi-state survival analysis[J]. J Clin Med, 2022, 11(12): 3425. DOI: 10.3390/jcm11123425.
    [42] BIFULCO O, BOTTIO T, CARAFFA R, et al. Marginal versus standard donors in heart transplantation: proper selection means heart transplant benefit[J]. J Clin Med, 2022, 11(9): 2665. DOI: 10.3390/jcm11092665.
    [43] CARAFFA R, BEJKO J, CARROZZINI M, et al. A device strategy-matched comparison analysis among different intermacs profiles: a single center experience[J]. J Clin Med, 2022, 11(16): 4901. DOI: 10.3390/jcm11164901.
    [44] KORMOS RL, COWGER J, PAGANI FD, et al. The society of thoracic surgeons intermacs database annual report: evolving indications, outcomes, and scientific partnerships[J]. J Heart Lung Transplant, 2019, 38(2): 114-126. DOI: 10.1016/j.healun.2018.11.013.
    [45] DE BY TMMH, MOHACSI P, GAHL B, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report[J]. Eur J Cardiothorac Surg, 2018, 53(2): 309-316. DOI: 10.1093/ejcts/ezx320.
    [46] HAYWARD C, ADACHI I, BAUDART S, et al. Global best practices consensus: long-term management of patients with hybrid centrifugal flow left ventricular assist device support[J]. J Thorac Cardiovasc Surg, 2022, 164(4): 1120-1137. DOI: 10.1016/j.jtcvs.2022.03.035.
    [47] TEUTEBERG JJ, CLEVELAND JC JR, COWGER J, et al. The Society of Thoracic Surgeons Intermacs 2019 annual report: the changing landscape of devices and indications[J]. Ann Thorac Surg, 2020, 109(3): 649-660. DOI: 10.1016/j.athoracsur.2019.12.005.
    [48] KIRKLIN JK, NAFTEL DC, PAGANI FD, et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? [J]. J Thorac Cardiovasc Surg, 2012, 144(3): 584-603. DOI: 10.1016/j.jtcvs.2012.05.044.
    [49] BOULET J, CUNNINGHAM JW, MEHRA MR. Cardiac xenotransplantation: challenges, evolution, and advances[J]. JACC Basic Transl Sci, 2022, 7(7): 716-729. DOI: 10.1016/j.jacbts.2022.05.003.
    [50] YAMADA K, YAZAWA K, SHIMIZU A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1, 3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue[J]. Nat Med, 2005, 11(1): 32-34. DOI: 10.1038/nm1172.
    [51] SATYANANDA V, HARA H, EZZELARAB MB, et al. New concepts of immune modulation in xenotransplantation[J]. Transplantation, 2013, 96(11): 937-945. DOI: 10.1097/TP.0b013e31829bbcb2.
    [52] RYCZEK N, HRYHOROWICZ M, ZEYLAND J, et al. CRISPR/Cas technology in pig-to-human xenotransplantation research[J]. Int J Mol Sci, 2021, 22(6): 3196. DOI: 10.3390/ijms22063196.
    [53] PORRETT PM, ORANDI BJ, KUMAR V, et al. First clinical-grade porcine kidney xenotransplant using a human decedent model[J]. Am J Transplant, 2022, 22(4): 1037-1053. DOI: 10.1111/ajt.16930.
    [54] DELTCHEVA E, CHYLINSKI K, SHARMA CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase Ⅲ[J]. Nature, 2011, 471(7340): 602-607. DOI: 10.1038/nature09886.
    [55] YANG L, GüELL M, NIU D, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs) [J]. Science, 2015, 350(6264): 1101-1104. DOI: 10.1126/science.aad1191.
    [56] NIU D, WEI HJ, LIN L, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9[J]. Science, 2017, 357(6357): 1303-1307. DOI: 10.1126/science.aan4187.
    [57] REARDON S. First pig-to-human heart transplant: what can scientists learn? [J]. Nature, 2022, 601(7893): 305-306. DOI: 10.1038/d41586-022-00111-9.
    [58] GRIFFITH BP, GOERLICH CE, SINGH AK, et al. Genetically modified porcine-to-human cardiac xenotransplantation[J]. N Engl J Med, 2022, 387(1): 35-44. DOI: 10.1056/NEJMoa2201422.
    [59] CLEVERS H. Modeling development and disease with organoids[J]. Cell, 2016, 165(7): 1586-1597. DOI: 10.1016/j.cell.2016.05.082.
    [60] HOFBAUER P, JAHNEL SM, PAPAI N, et al. Cardioids reveal self-organizing principles of human cardiogenesis[J]. Cell, 2021, 184(12): 3299-3317. DOI: 10.1016/j.cell.2021.04.034.
  • 加载中
图(2)
计量
  • 文章访问数:  331
  • HTML全文浏览量:  142
  • PDF下载量:  110
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-11-01
  • 网络出版日期:  2023-03-15
  • 刊出日期:  2023-03-15

目录

    /

    返回文章
    返回